Based in Pleasanton, California, Apton Biosystems is a developer of Super-Res sequencing and single-molecule protein detection systems. Their optical systems use super-resolution to evaluate molecules spaced closer than a wavelength of light. The company focuses on large-scale clinical applications, such as early cancer detection and population sequencing. Apton Biosystems' high-throughput and low-cost sequencing platform enables biomarker discovery, early disease detection, and therapeutic monitoring, advancing preventive health and precision medicine. In August 2023, the company was acquired by PacBio at a valuation between $85M and $110M.